Drugs / CD34+ stem cells
CD34+ stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00535197 | Sep 2007 → Jul 2012 | middle cerebral artery infarction | Imperial College London | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-09-25 | CellProthera | Results CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction cellprothera.com ↗
In these high-risk patients, CellProthera’s automated expansion platform reliably produced patient’s own expanded CD34+ stem cells at clinical scale. |
| 2024-07-12 | CellProthera | Results CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes© for the Treatment of Acute Myocardial Infarction cellprothera.com ↗
The ProtheraCytes, which are autologous, expanded CD34+ stem cells, were well tolerated with no unexpected serious adverse events reported. |
| 2024-07-08 | BioCardia, Inc. | Results CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction biocardia.com ↗
The ProtheraCytes, which are autologous, expanded CD34+ stem cells, were well tolerated with no unexpected serious adverse events reported. |
| 2019-06-15 | Editas Medicine, Inc. | Results Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association editasmedicine.com ↗
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a follow-up study to assess two different CRISPR genome editing strategies, one targeting the BCL11A erythroid enhancer ( BC11Ae ) and one targeting the beta-globin locus, for the treatment of sickle cell disease and beta-thalassemia. |
All press releases naming this drug 4 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34+ stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00535197 ↗ |
| Known as | CD34+ cells | “CD34+ cells were collected from the bone marrow of the subjects before being delivered by catheter angiography into the ipsilesional middle cerebral artery.” NCT00535197 ↗ |
| Known as | CD34+ hematopoietic stem/progenitor cells | “Treatment with CD34+ hematopoietic stem/progenitor cells has been shown to improve functional recovery in nonhuman models of ischemic stroke via promotion of angiogenesis and...” PMID 25107583 ↗ Aug 2014 |
| Modality | Cell therapy | “autologous, immunoselected CD34+ stem/progenitor cell therapy” PMID 25107583 ↗ Aug 2014 |
| Route | Other | “delivered intra-arterially” PMID 25107583 ↗ Aug 2014 |